ENTITY
Gracell Biotechnologies Inc

Gracell Biotechnologies Inc (GRCL US)

14
Analysis
Health CareUnited States
Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.
more
01 Jan 2024 09:23

China Healthcare Weekly (Dec.31)-New Medical Device Policy, AstraZeneca to Acquire Gracell, PD-1+ADC

As new policy prohibits public hospitals from borrowing to purchase medical device, investment logic changes. AZ-Gracell deal has epoch-making...

Logo
768 Views
Share
01 Aug 2024 08:55

Legend Biotech (LEGN.US) Offer Update - Some New Information About the Takeover Worth the Attention

The potential takeover seems reliable.Genscript will be a big winner but it's uncertain whether Genscript will offer dividends to small/medium...

Logo
536 Views
Share
21 Apr 2024 14:08

China Healthcare Weekly (Apr.21) - M&As in Biotech, Capital Is Bullish on Non-Tumor Sectors, Tofflon

​MNCs acquiring Chinese biotech companies, but domestic big pharma may not follow suit.Investment focus shifting to non-oncology fields.Tofflon is...

Logo
362 Views
Share
27 Oct 2023 22:17

CARGO Therapeutics IPO Preview: A Promising Pipeline of Next-Gen CAR T-Cell Therapies

​A VC-backed biotech firm CARGO Therapeutics filed for an IPO. The company develops CAR T-cell products for adult patients with relapsed or...

Logo
639 Views
Share
03 Jul 2023 08:55

Gracell Biotechnologies Inc (GRCL.US) - May Fail to Solve the Real Pain Points in CAR-T Field

Gracell's stock price would fluctuate with positive clinical data, but if it cannot fundamentally addresses the pain point of CAR-T, stock price...

Logo
376 Views
Share
x